Vericel Corporation
HealthcareNASDAQ:VCEL · NASDAQ Capital Market
-$1.11 today
Vol 0.36M · Avg 0.67M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $16.5M +59.4% | $10.4M +425.6% | -$3.2M +81.0% | -$16.7M -123.7% | -$7.5M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $11.4M +106.4% | $5.5M +18.8% | $4.6M +16.4% | $4.0M +34.3% | $3.0M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 -100.0% | $721.0K -24.0% | $949.0K | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $38.8M +6.2% | $36.5M +12.9% | $32.3M -13.1% | $37.2M +8.3% | $34.3M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$21.4M -4646.0% | -$450.0K +88.6% | -$4.0M +64.6% | -$11.2M -82.1% | -$6.2M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$23.3M -670.4% | -$3.0M +74.5% | -$11.8M -29.8% | -$9.1M -210.3% | -$2.9M | $592.6M | $1.3B | $626.2M |
| Inventory | -$1.2M +71.3% | -$4.3M -247.8% | $2.9M +211.3% | -$2.6M +35.3% | -$4.0M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $3.0M +1136.2% | -$287.0K -109.4% | $3.0M +112.2% | $1.4M -3.6% | $1.5M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $158.0K -97.8% | $7.1M +274.9% | $1.9M +302.9% | -$939.0K -36.7% | -$687.0K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $6.6M +5.9% | $6.3M +13.7% | $5.5M +47.8% | $3.7M -16.0% | $4.4M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $51.9M -10.8% | $58.2M +64.7% | $35.3M +99.6% | $17.7M -39.1% | $29.0M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$27.2M +57.5% | -$64.0M -132.5% | -$27.5M -262.2% | -$7.6M +4.0% | -$7.9M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 -100.0% | $7.6M -4.0% | $7.9M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$72.4M -6.1% | -$68.2M -23.5% | -$55.2M +20.6% | -$69.6M -15.9% | -$60.0M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $55.6M +4.6% | $53.2M -33.2% | $79.6M +94.4% | $40.9M -36.5% | $64.4M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 +100.0% | -$64.0M -132.5% | -$27.5M -262.2% | -$7.6M +4.0% | -$7.9M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$43.9M +44.4% | -$79.0M -2425.0% | -$3.1M +91.4% | -$36.2M -934.2% | -$3.5M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $13.9M -43.2% | $24.5M +308.6% | $6.0M +64.3% | $3.7M -67.3% | $11.2M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$6.9M -25.7% | -$5.5M -129.3% | -$2.4M +8.6% | -$2.6M -29.5% | -$2.0M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $7.1M -62.9% | $19.1M +426.6% | $3.6M +246.2% | $1.0M -88.6% | $9.2M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $15.0M +927.9% | -$1.8M -105.1% | $35.8M +304.9% | -$17.5M -150.3% | $34.7M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $24.7M +525.9% | -$5.8M -174.5% | $7.8M -22.7% | $10.1M -52.2% | $21.1M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.75B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.47B
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
$2.03B
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$1.99B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$1.96B
Mesoblast Limited
NASDAQ:MESO
$1.79B
uniQure N.V.
NASDAQ:QURE
$1.74B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.47B
MannKind Corporation
NASDAQ:MNKD
$1.13B
SEC Filings
Recent regulatory filings
No filings found.
Does VCEL generate free cash flow?
Vericel Corporation (VCEL) generated $24.75M of free cash flow in fiscal 2025.
How much operating cash flow does VCEL produce?
Operating cash flow was $51.91M, before capital expenditures of $27.16M.
Explore More
Continue the stock analysis
Jump to another research area for this company.